Kefeli Ayşe, Başyigit Sebahat, Yeniova Abdullah Ozgur, Ozkan Serdar, Nazligul Yasar
Gastroenterology Department, Siirt State Hospital, Siirt, Turkey.
Gastroenterology Department, Kecioren Training Hospital, Ankara, Turkey.
Arch Med Sci. 2018 Mar;14(2):276-280. doi: 10.5114/aoms.2016.58595. Epub 2016 Mar 16.
infection is a common infection worldwide. The most frequently recommended treatment for eradication of remains triple therapy. In this study, we compared sequential and hybrid regimens for eradication in a region of Turkey with high resistance to clarithromycin.
Three hundred and forty -positive patients were enrolled in the study. The subjects were randomly divided into two groups. The first group (170 patients) received rabeprazole (40 mg/b.i.d.) and amoxicillin (1000 mg/b.i.d.) for 2 weeks and metronidazole and clarithromycin (500 mg/b.i.d.) during the second week in the hybrid therapy group. The second group (170 patients) received rabeprazole (40 mg/b.i.d.) for 14 days, amoxicillin (1000 mg/b.i.d.) for the first 7 days, and metronidazole plus clarithromycin (each 500 mg/b.i.d.) during the next 7 days in the sequential therapy group.
In the per-protocol analysis, the eradication rate in the hybrid therapy group was 96.1% (147/153), and in the sequential therapy group it was 90.9% (140/154). There was no significant difference between the two groups ( = 0.06). Ninety-seven of those 340 patients reported minor adverse drug reactions. The percentages of patients with adverse reactions were 30.6% in the hybrid therapy group and 26.5% in the sequential therapy group ( = 0.74).
Both therapies are highly effective for eradication of , and could be recommended as a first-line therapy in regions with high antibiotic resistance.
感染是全球常见的感染类型。根除[具体感染名称未提及]最常推荐的治疗方法仍然是三联疗法。在本研究中，我们在土耳其一个对克拉霉素耐药性高的地区比较了序贯疗法和混合疗法对[具体感染名称未提及]的根除效果。
340例[具体感染名称未提及]阳性患者纳入本研究。受试者被随机分为两组。混合治疗组的第一组（170例患者）接受雷贝拉唑（40mg/每日两次）和阿莫西林（1000mg/每日两次）治疗2周，第二周加用甲硝唑和克拉霉素（500mg/每日两次）。序贯治疗组的第二组（170例患者）接受雷贝拉唑（40mg/每日两次）治疗14天，前7天加用阿莫西林（1000mg/每日两次），接下来7天加用甲硝唑加克拉霉素（各500mg/每日两次）。
在符合方案分析中，混合治疗组的根除率为96.1%（147/153），序贯治疗组为90.9%（140/154）。两组之间无显著差异（P = 0.06）。这340例患者中有97例报告了轻微的药物不良反应。混合治疗组不良反应患者的百分比为30.6%，序贯治疗组为26.5%（P = 0.74）。
两种疗法对根除[具体感染名称未提及]均高度有效，在抗生素耐药性高的地区可作为一线治疗推荐。
